What is Zimmer Biomet's earnings per share (EPS)?

Zimmer Biomet (ZBH) reported diluted earnings per share of $3.55 for fiscal year 2025. This represents a -19.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Zimmer Biomet Financials

ZBH

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Zimmer Biomet (ZBH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 53/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Zimmer Biomet has an operating margin of 13.3%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 52/100, indicating healthy but not exceptional operating efficiency. This is down from 16.7% the prior year.

Growth

Zimmer Biomet's revenue grew 7.2% year-over-year to $8.2B, a solid pace of expansion. This earns a growth score of 45/100.

Leverage

Zimmer Biomet carries a low D/E ratio of 0.55, meaning only $0.55 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 91/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Zimmer Biomet's current ratio of 1.98 indicates adequate short-term liquidity, earning a score of 36/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Zimmer Biomet converts 17.9% of revenue into free cash flow ($1.5B). This strong cash generation earns a score of 70/100.

Returns

Zimmer Biomet generates a 5.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 23/100. This is down from 7.2% the prior year.

Altman Z-Score Grey Zone

2.38

Zimmer Biomet scores 2.38, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Neutral

5/9

Zimmer Biomet passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

2.41x

For every $1 of reported earnings, Zimmer Biomet generates $2.41 in operating cash flow ($1.7B OCF vs $705.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

3.8x

Zimmer Biomet earns $3.8 in operating income for every $1 of interest expense ($1.1B vs $292.8M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$8.2B

YoY+7.2%

5Y CAGR+6.1%

10Y CAGR+3.2%

Zimmer Biomet generated $8.2B in revenue in fiscal year 2025. This represents an increase of 7.2% from the prior year.

EBITDA

$2.2B

YoY-3.9%

5Y CAGR+17.4%

10Y CAGR+6.4%

Zimmer Biomet's EBITDA was $2.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3.9% from the prior year.

Net Income

$705.1M

YoY-22.0%

10Y CAGR+17.0%

Zimmer Biomet reported $705.1M in net income in fiscal year 2025. This represents a decrease of 22.0% from the prior year.

EPS (Diluted)

$3.55

YoY-19.9%

10Y CAGR+16.5%

Zimmer Biomet earned $3.55 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 19.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.5B

YoY+13.7%

5Y CAGR+6.2%

10Y CAGR+8.0%

Zimmer Biomet generated $1.5B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 13.7% from the prior year.

Cash & Debt

$591.9M

YoY+12.6%

5Y CAGR-5.2%

10Y CAGR-8.6%

Zimmer Biomet held $591.9M in cash against $6.9B in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.96

YoY+0.0%

5Y CAGR+0.0%

10Y CAGR+0.9%

Zimmer Biomet paid $0.96 per share in dividends in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Shares Outstanding

196M

YoY-1.7%

5Y CAGR-1.2%

Zimmer Biomet had 196M shares outstanding in fiscal year 2025. This represents a decrease of 1.7% from the prior year.

Margins & Returns

Gross Margin

69.7%

YoY-1.7pp

5Y CAGR-0.5pp

10Y CAGR-0.3pp

Zimmer Biomet's gross margin was 69.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.7 percentage points from the prior year.

Operating Margin

13.3%

YoY-3.4pp

5Y CAGR+12.0pp

10Y CAGR+5.5pp

Zimmer Biomet's operating margin was 13.3% in fiscal year 2025, reflecting core business profitability. This is down 3.4 percentage points from the prior year.

Net Margin

8.6%

YoY-3.2pp

5Y CAGR+10.8pp

10Y CAGR+6.1pp

Zimmer Biomet's net profit margin was 8.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 3.2 percentage points from the prior year.

Return on Equity

5.5%

YoY-1.7pp

5Y CAGR+6.7pp

10Y CAGR+4.1pp

Zimmer Biomet's ROE was 5.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 1.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$458.5M

YoY+4.8%

5Y CAGR+7.3%

10Y CAGR+5.5%

Zimmer Biomet invested $458.5M in research and development in fiscal year 2025. This represents an increase of 4.8% from the prior year.

Share Buybacks

$487.0M

YoY-43.9%

10Y CAGR+12.5%

Zimmer Biomet spent $487.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 43.9% from the prior year.

Capital Expenditures

$224.5M

YoY+10.2%

5Y CAGR+14.9%

10Y CAGR+3.0%

Zimmer Biomet invested $224.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 10.2% from the prior year.

ZBH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$8.2B+7.2%	$7.7B+3.8%	$7.4B+6.5%	$6.9B+1.6%	$6.8B+11.4%	$6.1B
Cost of Revenue	$2.5B+13.8%	$2.2B+5.2%	$2.1B+3.2%	$2.0B+3.0%	$2.0B+7.5%	$1.8B
Gross Profit	$5.7B+4.6%	$5.5B+3.3%	$5.3B+7.9%	$4.9B+1.1%	$4.9B+13.1%	$4.3B
R&D Expenses	$458.5M+4.8%	$437.4M-4.6%	$458.7M+13.0%	$406.0M-6.8%	$435.8M+35.0%	$322.8M
SG&A Expenses	$3.3B+11.2%	$2.9B+3.2%	$2.8B+2.8%	$2.8B-2.9%	$2.8B+4.8%	$2.7B
Operating Income	$1.1B-14.6%	$1.3B+0.6%	$1.3B+83.5%	$696.3M-19.1%	$860.3M+935.3%	$83.1M
Interest Expense	-$292.8M-34.3%	-$218.0M-8.3%	-$201.2M-22.1%	-$164.8M+20.9%	-$208.4M+1.7%	-$212.1M
Income Tax	$125.7M-4.3%	$131.4M+211.4%	$42.2M-62.4%	$112.3M+109.9%	$53.5M+155.7%	-$96.0M
Net Income	$705.1M-22.0%	$903.8M-11.7%	$1.0B+342.5%	$231.4M-42.4%	$401.6M+389.1%	-$138.9M
EPS (Diluted)	$3.55-19.9%	$4.43-9.2%	$4.88+343.6%	$1.10-42.4%	$1.91+385.1%	$-0.67

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$2.2B+12.1%	$2.0B-3.7%	$2.1B+8.8%	$1.9B-5.6%	$2.0B+10.9%	$1.8B-6.1%	$1.9B+2.8%	$1.9B
Cost of Revenue	$792.4M+41.7%	$559.3M-5.6%	$592.2M+7.7%	$549.8M-6.3%	$586.7M+8.9%	$538.6M-2.7%	$553.6M+8.1%	$512.3M
Gross Profit	$1.5B+0.6%	$1.4B-2.9%	$1.5B+9.3%	$1.4B-5.4%	$1.4B+11.7%	$1.3B-7.4%	$1.4B+0.8%	$1.4B
R&D Expenses	$118.7M+2.4%	$115.9M+2.3%	$113.3M+2.4%	$110.6M+1.9%	$108.5M-2.8%	$111.6M+2.0%	$109.4M+1.4%	$107.9M
SG&A Expenses	$872.2M+7.5%	$811.4M-0.4%	$814.8M+7.4%	$758.8M+1.6%	$746.8M+5.2%	$709.7M-3.7%	$737.1M+0.1%	$736.2M
Operating Income	$154.5M-56.0%	$351.3M+17.1%	$300.0M+2.6%	$292.3M-24.9%	$389.0M+39.2%	$279.5M-20.4%	$351.3M+32.1%	$265.9M
Interest Expense	-$71.9M+4.6%	-$75.4M+4.9%	-$79.3M-19.8%	-$66.2M-6.9%	-$61.9M-14.0%	-$54.3M-6.3%	-$51.1M-0.8%	-$50.7M
Income Tax	-$40.0M-183.3%	$48.0M-32.6%	$71.2M+53.1%	$46.5M-4.9%	$48.9M+358.7%	-$18.9M-132.0%	$59.1M+39.7%	$42.3M
Net Income	$139.4M-39.6%	$230.9M+51.1%	$152.8M-16.0%	$182.0M-24.0%	$239.5M-3.9%	$249.1M+2.6%	$242.8M+40.8%	$172.4M
EPS (Diluted)	N/A	$1.16+50.6%	$0.77-15.4%	$0.91	N/A	$1.23+4.2%	$1.18+40.5%	$0.84

ZBH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$23.1B+8.1%	$21.4B-0.6%	$21.5B+2.0%	$21.1B-10.2%	$23.5B-3.9%	$24.4B
Current Assets	$5.1B+9.6%	$4.7B+1.3%	$4.6B+4.1%	$4.4B-9.4%	$4.9B-3.9%	$5.1B
Cash & Equivalents	$591.9M+12.6%	$525.5M+26.4%	$415.8M+10.7%	$375.7M-0.6%	$378.1M-51.2%	$774.7M
Inventory	$2.3B+2.3%	$2.2B-6.3%	$2.4B+11.1%	$2.1B0.0%	$2.1B-1.2%	$2.2B
Accounts Receivable	$1.7B+15.1%	$1.5B+2.7%	$1.4B+4.4%	$1.4B+9.7%	$1.3B-1.4%	$1.3B
Goodwill	$9.9B+11.1%	$9.0B+1.5%	$8.8B+2.8%	$8.6B-3.8%	$8.9B-0.7%	$9.0B
Total Liabilities	$10.4B+16.8%	$8.9B-1.3%	$9.0B-0.3%	$9.0B-16.2%	$10.8B-11.7%	$12.2B
Current Liabilities	$2.6B+5.4%	$2.5B-14.2%	$2.9B+21.2%	$2.4B-32.0%	$3.5B+35.6%	$2.6B
Long-Term Debt	$6.9B+29.8%	$5.3B+9.7%	$4.9B-5.5%	$5.2B-5.7%	$5.5B-28.4%	$7.6B
Total Equity	$12.7B+1.8%	$12.5B-0.1%	$12.5B+3.8%	$12.0B-5.1%	$12.7B+3.8%	$12.2B
Retained Earnings	$11.6B+4.6%	$11.1B+6.8%	$10.4B+8.6%	$9.6B-7.1%	$10.3B+2.0%	$10.1B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$23.1B-1.7%	$23.5B+2.7%	$22.9B+3.1%	$22.2B+3.8%	$21.4B-1.6%	$21.7B+0.9%	$21.5B+0.3%	$21.5B
Current Assets	$5.1B-12.3%	$5.8B+15.5%	$5.1B-9.6%	$5.6B+19.7%	$4.7B-4.0%	$4.9B+4.8%	$4.6B+0.2%	$4.6B
Cash & Equivalents	$591.9M-54.2%	$1.3B+132.1%	$556.9M-59.8%	$1.4B+163.5%	$525.5M-7.6%	$569.0M+35.4%	$420.1M+6.9%	$393.0M
Inventory	$2.3B-7.9%	$2.5B+1.2%	$2.5B+9.4%	$2.2B+0.4%	$2.2B-5.6%	$2.4B-0.1%	$2.4B-0.8%	$2.4B
Accounts Receivable	$1.7B+6.6%	$1.6B-0.8%	$1.6B+5.1%	$1.5B+3.6%	$1.5B-0.1%	$1.5B+4.5%	$1.4B-2.0%	$1.4B
Goodwill	$9.9B+2.5%	$9.7B-0.1%	$9.7B+8.0%	$9.0B+0.4%	$9.0B+0.4%	$8.9B+1.0%	$8.8B+0.4%	$8.8B
Total Liabilities	$10.4B-3.1%	$10.7B+3.8%	$10.3B+5.6%	$9.8B+10.0%	$8.9B-4.8%	$9.3B+6.5%	$8.8B-0.9%	$8.8B
Current Liabilities	$2.6B+7.5%	$2.4B-11.0%	$2.7B+17.6%	$2.3B-6.4%	$2.5B-31.4%	$3.6B-1.0%	$3.6B+29.0%	$2.8B
Long-Term Debt	$6.9B-7.7%	$7.5B+11.3%	$6.8B+2.7%	$6.6B+23.1%	$5.3B+12.7%	$4.7B+19.7%	$4.0B-18.0%	$4.8B
Total Equity	$12.7B-0.5%	$12.8B+1.8%	$12.5B+1.0%	$12.4B-0.6%	$12.5B+0.8%	$12.4B-2.9%	$12.7B+1.1%	$12.6B
Retained Earnings	$11.6B+0.8%	$11.5B+1.6%	$11.3B+0.9%	$11.2B+1.2%	$11.1B+1.8%	$10.9B+1.9%	$10.7B+1.8%	$10.5B

ZBH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.7B+13.2%	$1.5B-5.2%	$1.6B+16.6%	$1.4B-9.5%	$1.5B+24.5%	$1.2B
Capital Expenditures	$224.5M+10.2%	$203.8M-30.0%	$291.1M+54.9%	$187.9M+30.8%	$143.6M+28.3%	$111.9M
Free Cash Flow	$1.5B+13.7%	$1.3B+0.4%	$1.3B+10.5%	$1.2B-13.8%	$1.4B+24.1%	$1.1B
Investing Cash Flow	-$2.0B-122.5%	-$888.1M-14.0%	-$778.9M	N/A	-$503.6M+18.0%	-$613.8M
Financing Cash Flow	$326.0M+167.3%	-$484.5M+36.5%	-$763.5M	N/A	-$1.3B-209.6%	-$421.8M
Dividends Paid	$190.3M-2.9%	$196.0M-2.4%	$200.9M-0.1%	$201.2M+0.5%	$200.1M+0.8%	$198.5M
Share Buybacks	$487.0M-43.9%	$868.0M+25.4%	$692.2M+447.6%	$126.4M	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$517.4M+23.6%	$418.7M+10.7%	$378.2M-1.2%	$382.8M-24.4%	$506.3M+28.0%	$395.7M+7.1%	$369.4M+62.0%	$228.0M
Capital Expenditures	$74.8M+36.0%	$55.0M+9.8%	$50.1M+12.3%	$44.6M-13.4%	$51.5M+15.7%	$44.5M-15.6%	$52.7M-4.4%	$55.1M
Free Cash Flow	$442.6M+21.7%	$363.7M+10.9%	$328.1M-3.0%	$338.2M-25.6%	$454.8M+29.5%	$351.2M+10.9%	$316.7M+83.2%	$172.9M
Investing Cash Flow	-$322.0M-97.2%	-$163.3M+88.2%	-$1.4B-1206.0%	-$106.0M+63.6%	-$291.2M-88.0%	-$154.9M+37.3%	-$247.0M-26.7%	-$195.0M
Financing Cash Flow	-$897.0M-285.4%	$483.8M+195.4%	$163.8M-71.5%	$575.4M+339.2%	-$240.6M-136.1%	-$101.9M-10.9%	-$91.9M-83.4%	-$50.1M
Dividends Paid	$47.5M0.0%	$47.5M0.0%	$47.5M-0.6%	$47.8M-0.4%	$48.0M-2.4%	$49.2M-0.4%	$49.4M0.0%	$49.4M
Share Buybacks	$250.0M	$0-100.0%	$7.2M-96.9%	$229.8M+218.3%	$72.2M-87.9%	$596.3M+594.2%	$85.9M-24.4%	$113.6M

ZBH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	69.7%-1.7pp	71.5%-0.4pp	71.8%+0.9pp	70.9%-0.4pp	71.3%+1.1pp	70.2%
Operating Margin	13.3%-3.4pp	16.7%-0.5pp	17.3%+7.3pp	10.0%-2.6pp	12.6%+11.2pp	1.4%
Net Margin	8.6%-3.2pp	11.8%-2.1pp	13.9%+10.5pp	3.3%-2.5pp	5.9%+8.2pp	-2.3%
Return on Equity	5.5%-1.7pp	7.2%-1.0pp	8.2%+6.3pp	1.9%-1.2pp	3.2%+4.3pp	-1.1%
Return on Assets	3.0%-1.2pp	4.2%-0.5pp	4.8%+3.7pp	1.1%-0.6pp	1.7%+2.3pp	-0.6%
Current Ratio	1.98+0.1	1.91+0.3	1.61-0.3	1.88+0.5	1.41-0.6	1.99
Debt-to-Equity	0.55+0.1	0.43+0.0	0.39-0.0	0.430.0	0.43-0.2	0.63
FCF Margin	17.9%+1.0pp	16.9%-0.6pp	17.4%+0.6pp	16.8%-3.0pp	19.9%+2.0pp	17.8%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	64.7%-7.4pp	72.0%+0.6pp	71.5%+0.3pp	71.2%+0.2pp	71.0%+0.5pp	70.5%-1.0pp	71.5%-1.4pp	72.9%
Operating Margin	6.9%-10.7pp	17.5%+3.1pp	14.4%-0.9pp	15.3%-3.9pp	19.2%+3.9pp	15.3%-2.8pp	18.1%+4.0pp	14.1%
Net Margin	6.2%-5.3pp	11.5%+4.2pp	7.4%-2.2pp	9.5%-2.3pp	11.8%-1.8pp	13.7%+1.2pp	12.5%+3.4pp	9.1%
Return on Equity	1.1%-0.7pp	1.8%+0.6pp	1.2%-0.2pp	1.5%-0.4pp	1.9%-0.1pp	2.0%+0.1pp	1.9%+0.5pp	1.4%
Return on Assets	0.6%-0.4pp	1.0%+0.3pp	0.7%-0.2pp	0.8%-0.3pp	1.1%-0.0pp	1.1%+0.0pp	1.1%+0.3pp	0.8%
Current Ratio	1.98-0.4	2.43+0.6	1.87-0.6	2.44+0.5	1.91+0.5	1.36+0.1	1.29-0.4	1.66
Debt-to-Equity	0.55-0.0	0.59+0.0	0.540.0	0.53+0.1	0.43+0.0	0.38+0.1	0.31-0.1	0.38
FCF Margin	19.7%+1.6pp	18.2%+2.4pp	15.8%-1.9pp	17.7%-4.8pp	22.5%+3.2pp	19.3%+2.9pp	16.3%+7.2pp	9.2%

Similar Companies

$13.6B

$26.0B

$21.6B

$14.6B

$24.0B

Frequently Asked Questions

What is Zimmer Biomet's annual revenue?

Zimmer Biomet (ZBH) reported $8.2B in total revenue for fiscal year 2025. This represents a 7.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Zimmer Biomet's revenue growing?

Zimmer Biomet (ZBH) revenue grew by 7.2% year-over-year, from $7.7B to $8.2B in fiscal year 2025.

Is Zimmer Biomet profitable?

Yes, Zimmer Biomet (ZBH) reported a net income of $705.1M in fiscal year 2025, with a net profit margin of 8.6%.

What is Zimmer Biomet's EBITDA?

Zimmer Biomet (ZBH) had EBITDA of $2.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Zimmer Biomet have?

As of fiscal year 2025, Zimmer Biomet (ZBH) had $591.9M in cash and equivalents against $6.9B in long-term debt.

What is Zimmer Biomet's gross margin?

Zimmer Biomet (ZBH) had a gross margin of 69.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Zimmer Biomet's operating margin?

Zimmer Biomet (ZBH) had an operating margin of 13.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Zimmer Biomet's net profit margin?

Zimmer Biomet (ZBH) had a net profit margin of 8.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Zimmer Biomet pay dividends?

Yes, Zimmer Biomet (ZBH) paid $0.96 per share in dividends during fiscal year 2025.

What is Zimmer Biomet's return on equity (ROE)?

Zimmer Biomet (ZBH) has a return on equity of 5.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Zimmer Biomet's free cash flow?

Zimmer Biomet (ZBH) generated $1.5B in free cash flow during fiscal year 2025. This represents a 13.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Zimmer Biomet's operating cash flow?

Zimmer Biomet (ZBH) generated $1.7B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Zimmer Biomet's total assets?

Zimmer Biomet (ZBH) had $23.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Zimmer Biomet's capital expenditures?

Zimmer Biomet (ZBH) invested $224.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Zimmer Biomet spend on research and development?

Zimmer Biomet (ZBH) invested $458.5M in research and development during fiscal year 2025.

Does Zimmer Biomet buy back shares?

Yes, Zimmer Biomet (ZBH) spent $487.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Zimmer Biomet have outstanding?

Zimmer Biomet (ZBH) had 196M shares outstanding as of fiscal year 2025.

What is Zimmer Biomet's current ratio?

Zimmer Biomet (ZBH) had a current ratio of 1.98 as of fiscal year 2025, which is generally considered healthy.

What is Zimmer Biomet's debt-to-equity ratio?

Zimmer Biomet (ZBH) had a debt-to-equity ratio of 0.55 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Zimmer Biomet's return on assets (ROA)?

Zimmer Biomet (ZBH) had a return on assets of 3.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Zimmer Biomet's Altman Z-Score?

Zimmer Biomet (ZBH) has an Altman Z-Score of 2.38, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Zimmer Biomet's Piotroski F-Score?

Zimmer Biomet (ZBH) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Zimmer Biomet's earnings high quality?

Zimmer Biomet (ZBH) has an earnings quality ratio of 2.41x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Zimmer Biomet cover its interest payments?

Zimmer Biomet (ZBH) has an interest coverage ratio of 3.8x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Zimmer Biomet?

Zimmer Biomet (ZBH) scores 53 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.